Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results

Author:Querol, Luis   Lewis, Richard A.   Hartung, Hans-Peter   van Doorn, Pieter A.   Lin, Jie   Dionne, Annie   Attarian, Shahram   Wallstroem, Erik   Auwarter, Kristen   Lu, Yi   Alonso-Alonso, Miguel   Atassi, Nazem   Hughes, Richard A. C.   

Session Name:S2: Updates on Motor Neuron and Peripheral Nerve Disorders  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S2.008  

Author Institution:Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain  Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain, Spain  Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA, USA, CA  Department of Neurology, Faculty of Medicine, Heinrich-Heine-University, Düsseldorf, Germany  Brain and Mind Center, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Palacky University Olomouc, Olomouc, The Czech Republic, Dusseldorf, Germany  Erasmus MC, University Medical Center, Rotterdam, The Netherlands, Netherlands  Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, People's Republic of  CHU de Quebec Universite Laval, Quebec, Canada, QC, Canada  Neuromuscular Disease and ALS Reference Center, Timone University Hospital, Aix-Marseille University, CHU Timone, Marseille Cedex 05, France, France  Sanofi R&D, Neurology Development, Cambridge, MA, USA, Cambridge, MA  Sanofi, USA, MA  Sanofi R&D, Biostatistics and Programming, Cambridge, MA, USA, CA  Sanofi R&D, Neurology Development, Cambridge, MA, USA, MA  UCL Queen Square Institute of Neurology, University College London, London, UK, United Kingdom  

Humoral Vaccine Responses and One-year Follow-up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-label, Phase IV Studies MINORE and SOPRANINO

Author:Dobson, Ruth   Bove, Riley   Hellwig, Kerstin   Oreja-Guevara, Celia   Derfuss, Tobias J.   Shah, Anna   Graham, Edith L.   McElrath, Thomas F.   Pietrasanta, Carlo   Maillart, Elisabeth   Jacobs, Dina   Kazlauskaite, Agne   Alves, Daniela   Raposo, Catarina   Craveiro, Licinio   Lin, Chien-Ju   Pasquarelli, Noemi   Vukusic, Sandra   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.002  

Author Institution:Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK, London, United Kingdom  Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA, Berkeley, CA  Katholisches Klinikum Bochum, St. Josef Hospital, Universitätsklinikum, Bochum, Germany, Bochum, Germany  Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain, Madrid, Spain  University Hospital Basel, University of Basel, Basel, Switzerland, Basel, Switzerland  Rocky Mountain MS Center, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Multiple Sclerosis and Neuroimmunology, Northwestern University, Chicago, IL, USA, Chicago, IL  Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA  NICU, Department of Woman, Child and Newborn, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Milan, Italy  Neurology Department, Hôpital de la Pitié Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France, Paris, France  Department of Neurology, Perelman School of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  Service de Neurologie et Sclérose en Plaques, Fondation Eugène Devic EDMUS contre la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Lyon, France, BRON Cedex, France  

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study

Author:Bar-Or, Amit   Oh, Jiwon   Giovannoni, Gavin   Sormani, Maria Pia   Weber, Martin S.   Stoll, Sharon   Nicholas, Jacqueline A.   Büdingen, H.-Christian von   Lopez, Jon   Roberts, Louise   Triyatni, Miriam   Qi, Qi   Ratchford, John N.   Napieralski, Julie   Goodyear, Alexandra   Hauser, Stephen L.   Kappos, Ludwig   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.004  

Author Institution:Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada  Queen Mary University of London, London, UK, London, United Kingdom  University of Genoa, Genoa, Italy, Genoa, Italy  Institute of Neuropathology and Department of Neurology, University Medical Center and Fraunhofer Institute for Translational Medicine and Pharmacology, Göttingen, Germany, Göttingen, Germany  Advocare Stoll Medical Group, Philadelphia, PA, USA, Philadelphia, PA  OhioHealth Multiple Sclerosis Centre, Riverside Methodist Hospital, Columbus, OH, USA, Columbus, OH  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., South San Francisco, CA, USA, South San Francisco, CA  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  University Hospital and University Basel, Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Basel, Switzerland, Basel, Switzerland  

Convergent Causal Mapping of Memory and a Brain Stimulation Target for Memory Dysfunction

Author:Howard, Calvin   Kwon, Simon   Madan, Savir   Garimella, Arun   Schaper, Frederic   Kletenik, Isaiah   Ng, Marcus   Mosley, Philip   Grafman, Jordan   Bakshi, Rohit   Glanz, Bonnie   Fosdick, Lisa   Johnson, Amy   Colyer, Ryan   Lyketsos, Constantine   Morton-Dutton, Mae   Giftakis, John   Temel, Yasin   Rouhl, Rob   Ko, Ji Hyun   Schmahl, Rabea   Baldermann, Juan   Andrade-Montemayor, Pablo   Visser-Vandewalle, Veerle   Kuhn, Jens   Corbetta, Maurizio   Fisher, Robert   Picht, Thomas   Faust, Katharina   Hermiller, Molly   Voss, Joel   Chitnis, Tanuja   Kahana, Michael   Smith, Gwenn   Lozano, Andres   Siddiqi, Shan   Horn, Andreas   Fox, Michael   

Session Name:S42: Perspectives on Non-Alzheimer's Dementia Diagnostics and Therapeutics  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:S42.007  

Author Institution:Calvin Howard, Boston, MA  Brigham and Women's Hospital, MA  Harvard Medical School, MA  Brigham and Women's, Boston, MA  BRIGHAM AND WOMEN’S HOSPITAL, Boston, MA  University of Manitoba, Winnipeg, MB, Canada  Queensland Brain Institute, Australia  Cognitive Neuroscience Section, Bethesda, MD  Harvard Medical School, Boston, MA  Brigham and Women'S Hospital, Boston, MA  Functional Neuromodulation Inc., MN  University of Manitoba, MB, Canada  University of Pennsylvania, PA  Johns Hopkins Medicine, Baltimore, MD  Medtronic, MN  Maastricht University Medical Center, Netherlands  University of Cologne, Germany  Department of Neurology, Washington University School of Medicine, Saint Louis, MO  Stanford University Medical Center, Palo Alto, CA  Charite Universitatmedizin Berlin, Germany  Dusseldorf University, Germany  Florida State University, FL  , University of Chicago, Chicago, IL  University of Pennsylvania, Merion Station, PA  Johns Hopkins Medicine, MD  Toronto Western Hosp, Toronto, ON, Canada  University Hospital Cologne, Germany  Brigham and Women's Hospital / Harvard Medical School, Boston, MA  

Immunosuppressive Therapies in Down Syndrome Regression Disorder: A Prospective Observational Cohort Study

Author:Santoro, Jonathan   Kazerooni, Lilia   Lucas, Maeve   Yousuf, Mariam   Otey, Samuel   Nguyen, Lina   Anadani, Nidhiben   Manning, Melanie   Rachubinski, Angela   Kammeyer, Ryan   Spinazzi, Noemi   Franklin, Catherine   Quinn, Eileen   Espinosa, Joaquin   Rafii, Michael   

Session Name:N2: Neuroscience in the Clinic: Neurological Care of Individuals with Down Syndrome Across the Lifespan  

Topic:Child Neurology and Developmental Neurology  

Program Number:N2.002  

Author Institution:Department of Neurology, Children's Hospital Los Angeles, Los Angeles, CA  Children's Hospital Los Angeles, Los Angeles, CA  Children's Hospital Los Angeles, CA  University Of Oklahoma Health Science Center, Oklahoma City, OK  Stanford School of Medicine, Palo Alto, CA  Linda Crnic Institute for Down Syndrome, Aurora, CO  Childrens Hospital Colorado, Aurora, CO  University of California San Francisco, Oakland, CA  The University of Queensland, South Brisbane, Australia  University of Toledo, Toledo, OH  USC Alzheimer'S Therapeutic Research Institute, San Diego, CA